Table 2. Second experimental group undergoing proteomic analysis: IOP, axial length and axon loss.
| Strain | Time | IOP versus control | % axial length Increase | % axon loss |
|---|---|---|---|---|
| CD1 |
1 week |
6.26 + 3.0** |
6.1±1.7* |
13.71±27.7 |
| 6 weeks |
5.6 + 3.3** |
9.6±4.0* |
−1.5±4.5 |
|
| B6 |
1 week |
11.1±7.4** |
10.3±0.07** |
−5.3±9.9 |
| 6 weeks |
7.7±3.6** |
9.1±7.8** |
9.5±15.9 |
|
| Aca23 | 1 week |
5.6±3.7** |
3.0 ± 0.03* |
−1.5±13.9 |
| 6 weeks | 5.3±4.8** | 3.0 ±.04 | −10.08±24.0 |
% axon loss is median compared to pooled controls. IOP is mean difference in IOP compared to untreated fellow eye over the time period. Axial length is compared to individual fellow control eye; n=5 scleras per time point. Data are mean±standard deviation. Minus % axon loss indicates higher number of axons in glaucoma eye than fellow=no damage. *=p<0.05 and **=p<0.01, t test comparing glaucoma to fellow eye control.